
Hodgkin Lymphoma 2025 UPDATE
Two Onc Docs
00:00
Nodular lymphocyte‑predominant Hodgkin's approach
Kareen contrasts NLPHL: CD20 positivity, indolent course, rituximab‑based therapy and observation for asymptomatic patients.
Play episode from 13:49
Transcript


